Where can I find news about VCYT?

The latest headlines, third-party analysis, and SEC filings for Veracyte, Inc. (VCYT) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.

Where are VCYT's SEC filings?

Veracyte, Inc. (VCYT)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

Where are VCYT's earnings call transcripts?

Full earnings call transcripts for Veracyte, Inc. (VCYT), with prepared remarks plus speaker-by-speaker analyst Q&A, live on the Earnings tab alongside the Earnings Reports section that links each quarter's press release and SEC report.

VCYT

Veracyte, Inc.

NASDAQ·Medical, Diagnostics & Research · Healthcare

$47.93$1.89+4.11%

Market cap$3.85B·Market closed·Oct 23 4:00 PM EDT

News & Analysis

Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO
globenewswire.comOct 23, 2026 · 4:00 AM
Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?
Veracyte (VCYT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zacks.comOct 21, 2026 · 1:11 PM
Veracyte (NASDAQ:VCYT) Stock Price Breaks Below 200 Day Moving Average – Should You Sell?
Veracyte, Inc. (NASDAQ: VCYT - Get Free Report)'s share price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $45.25 and traded as low as $43.45. Veracyte shares last traded at $43.80, with a volume of 725,427 shares. Analyst Ratings Changes Several analysts recently issued reports on
defenseworld.netOct 20, 2026 · 3:41 AM
Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that six studies involving its genomic tests will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain.
globenewswire.comOct 19, 2026 · 8:00 AM
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer
globenewswire.comOct 16, 2026 · 9:15 AM
Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter 2026 after the close of market on Wednesday, November 4, 2026.
globenewswire.comOct 14, 2026 · 4:05 PM
Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting.
globenewswire.comSep 29, 2026 · 8:00 AM
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
Six oral presentations and two posters will highlight Decipher's prognostic and predictive value in identifying patients' risk of progression and likelihood of benefiting from treatment intensification Six oral presentations and two posters will highlight Decipher's prognostic and predictive value in identifying patients' risk of progression and likelihood of benefiting from treatment intensification
globenewswire.comSep 25, 2026 · 5:12 PM

SEC Filings

8-K
Sep 14, 2026View on SEC
10-Q
Jul 31, 2026View on SEC
8-K
Jul 30, 2026View on SEC
8-K
Jun 11, 2026View on SEC
S-8
Jun 10, 2026View on SEC
SC 13G/A
Jun 5, 2026View on SEC

Frequently Asked Questions About VCYT

Where can I find news about VCYT?: The latest headlines, third-party analysis, and SEC filings for Veracyte, Inc. (VCYT) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.
Where are VCYT's SEC filings?: Veracyte, Inc. (VCYT)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
Where are VCYT's earnings call transcripts?: Full earnings call transcripts for Veracyte, Inc. (VCYT), with prepared remarks plus speaker-by-speaker analyst Q&A, live on the Earnings tab alongside the Earnings Reports section that links each quarter's press release and SEC report.

Veracyte, Inc.

Frequently Asked Questions About VCYT

Veracyte, Inc.

Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer

Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?

Veracyte (NASDAQ:VCYT) Stock Price Breaks Below 200 Day Moving Average – Should You Sell?

Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026

Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test

Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026

Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026

Frequently Asked Questions About VCYT

Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer

Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?

Veracyte (NASDAQ:VCYT) Stock Price Breaks Below 200 Day Moving Average – Should You Sell?

Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026

Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test

Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026

Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026